# Study on GS300 on NAFLD

> **NCT04887766** · NA · UNKNOWN · sponsor: **Gelesis, Inc.** · enrollment: 250 (estimated)

## Conditions studied

- Nonalcoholic Fatty Liver
- Weight Loss

## Interventions

- **DEVICE:** GS300
- **DEVICE:** Placebo

## Key facts

- **NCT ID:** NCT04887766
- **Lead sponsor:** Gelesis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04887766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04887766, "Study on GS300 on NAFLD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04887766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*